AWM
GSK icon

Apollon Wealth Management’s GSK GSK Stock Holding History

Apollon Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$914K Sell
16,556
-2,565
-13% -$139K 0.01% 639
2025
Q4 		$938K Buy
19,121
+917
+5% +$42.8K 0.02% 599
2025
Q3 		$786K Buy
18,204
+621
+4% +$24.3K 0.01% 667
2025
Q2 		$675K Sell
17,583
-76
-0.4% -$2.9K 0.01% 684
2025
Q1 		$684K Sell
17,659
-620
-3% -$22.7K 0.02% 624
2024
Q4 		$618K Buy
18,279
+1,634
+10% +$58.8K 0.01% 673
2024
Q3 		$680K Sell
16,645
-62
-0.4% -$2.54K 0.02% 606
2024
Q2 		$643K Sell
16,707
-813
-5% -$34.2K 0.02% 593
2024
Q1 		$751K Sell
17,520
-2,240
-11% -$92.4K 0.02% 549
2023
Q4 		$732K Buy
19,760
+9,145
+86% +$328K 0.03% 553
2023
Q3 		$385K Buy
10,615
+799
+8% +$28.4K 0.02% 621
2023
Q2 		$350K Buy
9,816
+382
+4% +$13.7K 0.02% 702
2023
Q1 		$336K Sell
9,434
-873
-8% -$30.5K 0.02% 653
2022
Q4 		$362K Sell
10,307
-1,560
-13% -$52K 0.03% 606
2022
Q3 		$349K Buy
11,867
+3,509
+42% +$133K 0.03% 554
2022
Q2 		$455K Sell
8,358
-111
-1% -$6.13K 0.04% 449
2022
Q1 		$461K Buy
8,469
+486
+6% +$26.4K 0.03% 483
2021
Q4 		$440K Buy
+7,983
New +$415K 0.03% 491
2020
Q3 		– Sell
-673
Closed -$34K – 366
2020
Q2 		$34K Buy
+673
New +$34.5K 0.02% 297

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Apollon Wealth Management's GSK Position: Q1 2026 in Review

Apollon Wealth Management reduced its GSK (GSK) stake by 13% in Q1 2026, selling an estimated $139K and leaving 16,556 shares worth $914K. The position accounts for 0.01% of the portfolio, ranked #639.

Apollon Wealth Management first reported a position in GSK in Q2 2020 and has held it in 19 quarters since. The position peaked at $938K in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Apollon Wealth Management held 16,556 shares of GSK worth $914K as of Q1 2026.
  • Apollon Wealth Management sold 2,565 GSK shares in Q1 2026, an estimated $139K.
  • GSK made up 0.01% of Apollon Wealth Management's portfolio in Q1 2026, its #639 holding.
  • Apollon Wealth Management first reported a position in GSK in Q2 2020 and has held it in 19 quarters since.
  • Apollon Wealth Management's GSK position peaked at $938K in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.